TMB and BRAF mutation status are independent predictive factors in high-risk melanoma patients with adjuvant anti-PD-1 therapy

BACKGROUND: High tumor mutational burden (TMB) is associated with a favorable outcome in metastatic melanoma patients treated with immune checkpoint inhibitors. However, data are limited in the adjuvant setting. As BRAF mutated patients have an alternative with targeted adjuvant therapy, it is impor...

Descripción completa

Detalles Bibliográficos
Autores principales: Eckardt, Julia, Schroeder, Christopher, Martus, Peter, Armeanu-Ebinger, Sorin, Kelemen, Olga, Gschwind, Axel, Bonzheim, Irina, Eigentler, Thomas, Amaral, Teresa, Ossowski, Stephan, Rieß, Olaf, Flatz, Lukas, Garbe, Claus, Forschner, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Article – Clinical Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931777/
https://www.ncbi.nlm.nih.gov/pubmed/35192052
http://dx.doi.org/10.1007/s00432-022-03939-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9931777/
https://www.ncbi.nlm.nih.gov/pubmed/35192052
http://dx.doi.org/10.1007/s00432-022-03939-w

Ejemplares similares